References

Completion dissection or observation for sentinel-node metastasis in melanoma

10.1056/nejmoa1613210 · 2017 · External reference

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

10.1016/s1470-2045(16)00141-8 · 2016 · External reference

Unresolved reference

External reference

Surgeon decision-making for management of positive sentinel lymph nodes in the post-Multicenter Selective Lymphadenectomy Trial II era: a survey study

10.1002/jso.26302 · 2021 · External reference

Melanoma sentinel lymph node biopsy and completion lymph node dissection: a regional hospital experience

10.1016/j.bjps.2021.09.077 · 2022 · External reference

Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions

10.4081/oncol.2019.433 · 2019 · External reference

Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma

10.1007/s11864-018-0575-4 · 2018 · External reference

Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update

10.1245/s10434-017-6267-7 · 2018 · External reference

Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States

10.1245/s10434-008-9885-2 · 2008 · External reference

Melanoma nodal management in Ontario the year after the 2012 American Society of Clinical Oncology and Society of Surgical Oncology guideline

10.3747/co.26.5123 · 2019 · External reference

National practice patterns of completion lymph node dissection for sentinel node-positive melanoma

10.1002/jso.25160 · 2018 · External reference

Practice variation in Sentinel Lymph Node Biopsy for melanoma patients in different geographical regions in the Netherlands

10.1016/j.suronc.2017.08.006 · 2017 · External reference

Trends in sentinel lymph node biopsy enactment for cutaneous melanoma

10.1245/s10434-019-07204-2 · 2019 · External reference

Evidence and implementation gaps in management of sentinel node-positive melanoma in the United States

10.1016/j.surg.2021.12.025 · 2022 · External reference

Survival analysis and sentinel lymph node status in thin cutaneous melanoma: a multicenter observational study

10.1002/cam4.2358 · 2019 · External reference

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

10.1016/j.jclinepi.2007.11.008 · 2008 · External reference

Toxicity and response criteria of the Eastern Cooperative Oncology Group

10.1097/00000421-198212000-00014 · 1982 · External reference

¿Is mitotic rate still useful in the management of patients with thin melanoma?

10.1111/jdv.14485 · 2017 · External reference

Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis

10.1097/00008390-200506000-00005 · 2005 · External reference

Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and dewar topography criteria

10.1200/jco.2010.31.6760 · 2011 · External reference

Análisis multicéntrico del manejo quirúrgico y tratamiento adyuvante de los pacientes con melanoma y positividad en la biopsia selectiva del ganglio centinela

10.1016/j.ad.2024.07.017 · 2025 · External reference

The enigma of regional lymph nodes in melanoma

10.1056/nejme1704290 · 2017 · External reference

Surveillance of sentinel node-positive melanoma patients with reasons for exclusion from MSLT-II: multi-institutional propensity score matched analysis

10.1016/j.jamcollsurg.2020.11.014 · 2021 · External reference

When is it worth performing lymphadenectomy in patients with melanoma micrometastases? A 20-year experience retrospective analysis

2021 · External reference

Lymph node dissection for melanoma: where do we stand?

10.2217/mmt-2016-0023 · 2017 · External reference

Implications of tumor-positive sentinel lymph nodes in single vs multiple nodal basins in melanoma

10.3389/fonc.2024.1416685 · 2024 · External reference

Recurrence factors in patients with cutaneous melanoma and positive sentinel lymph node treated in a single reference unit in Buenos Aires

2024 · External reference

Nodal recurrence is a primary driver of early relapse for patients with sentinel lymph node-positive melanoma in the modern therapeutic era

10.1245/s10434-021-09804-3 · 2021 · External reference

Predicting regional lymph node recurrence in the modern age of tumor-positive sentinel node melanoma: the role of the first postoperative ultrasound

10.1245/s10434-022-12345-y · 2022 · External reference

The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care

10.1080/14737140.2018.1489246 · 2018 · External reference

Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

2017 · External reference

Melanoma staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond

10.1245/s10434-018-6513-7 · 2018 · External reference

Stage III Melanoma: A Proposed Staging Model That Outperforms the American Joint Committee on Cancer Eighth Edition Staging System

10.1097/pas.0000000000002269 · 2024 · External reference

The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection

10.1016/j.ejca.2020.04.022 · 2020 · External reference

Risk factors for nodal recurrence after lymphadenectomy for melanoma

10.1007/s10434-001-0109-2 · 2001 · External reference

Nomograms to predict recurrence and survival in stage IIIB and IIIC melanoma after therapeutic lymphadenectomy

10.1016/j.ejca.2014.02.010 · 2014 · External reference

Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?

10.1245/s10434-008-0024-x · 2008 · External reference

The distribution of microscopic melanoma metastases in sentinel lymph nodes

10.1097/pas.0b013e31826d25f9 · 2012 · External reference

Survival in patients with sentinel node-positive melanoma with extranodal extension

2021 · External reference

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

10.1093/annonc/mdx176 · 2017 · External reference

Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600-mutated metastatic melanoma: pooled analysis of 4 randomized clinical trials

10.1001/jamaoncol.2018.2668 · 2018 · External reference

Real-world data on PD-1 inhibitor therapy in metastatic melanoma

10.1080/0284186x.2019.1620966 · 2019 · External reference

Development and validation of a prognostic risk model for patients with advanced melanoma treated with immune checkpoint inhibitors

10.1093/oncolo/oyad073 · 2023 · External reference

Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis

10.1007/s12672-022-00538-6 · 2022 · External reference

Predictors of survival in immunotherapy-based treatments in advanced melanoma: a meta-analysis

10.1111/ijd.17379 · 2025 · External reference

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

10.1016/s1470-2045(15)70122-1 · 2015 · External reference

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

10.1056/nejmoa1709030 · 2017 · External reference

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

10.1016/s1470-2045(20)30494-0 · 2020 · External reference

Tumor mitotic rate is an independent predictor of survival for nonmetastatic melanoma

2018 · External reference

Does mitotic rate predict sentinel lymph node metastasis or survival in patients with intermediate and thick melanoma?

10.1016/j.amjsurg.2010.07.037 · 2010 · External reference

Tumor mitotic rate added to the equation: melanoma prognostic factors changed? A single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients

10.1245/s10434-014-4349-3 · 2015 · External reference